Methods for predicting multiple myeloma treatment response

摘要

The present invention relates to a method of testing whether a patient suffering of myeloma will respond or not to a histone deacetylase inhibitor (HDACi) comprising: determining the expression level (ELi) of several genes G₁-G_n selected from table A in a biological sample obtained from said patient comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) iii) calculating the HAS score trough the following formula wherein βi represent the regression β coefficient reference value for the gene G_i and Ci=1 if the expression of the gene G_i (ELi) is higher than the predetermined reference level (ELRi) or Ci=−1 if the expression of the gene (ELi) is lower than or equal to the predetermined reference level (ELRi) comparing the score HAS determined at step iii) with a predetermined reference value HAS_R v) and concluding that the patient will respond to the HDACi when the HAS score is higher than the predetermined reference value HAS_R or concluding that the patient will not respond to the HDACi when the HAS score is lower than the predetermined value HAS_R.; $$ \begin{array}{cc}\mathrm{HAS}=\sum _{i=1}^n\beta i\times \mathrm{Ci}& \left(I\right)\end{array}$$